Treatment of Newly Diagnosed Glioblastoma in Patients Over Age 70 with Good Functional Status (MGMT Promoter Unmethylated)

Clinical Scenario

This protocol covers adults over the age of 70 who present with a new diagnosis of glioblastoma, maintain good functional status, and whose tumor carries an unmethylated MGMT promoter. Treatment decisions in this population are shaped by age, performance status, MGMT methylation status, and individual patient care goals.

Key Patient Factors

Age older than 70 years is the defining characteristic of this population. Patients who retain good performance status are considered candidates for active treatment — an approach that parallels the strategy used in younger patients. MGMT promoter unmethylated status is a relevant molecular factor that influences which treatment options are most appropriate. Given the modest benefit of standard treatments in this setting, enrollment in a clinical trial is highly recommended when one is available.

Treatment Approach (Partial Overview)

When a clinical trial is not accessible, management involves a form of radiotherapy combined with chemotherapy — with the choice between standard and shortened schedules depending on individual patient factors. The full protocol specifies the available options, the criteria guiding each choice, and any additional adjuncts that may be considered.

Instant Access to Structured Evidence-Based Regimens

References

Treatment decisions for glioblastoma after maximal safe resection depend on age, functional status, MGMT status, and patient care goals (Figure 8).

Given the modest benefits of standard treatments, participation in clinical trials is highly recommended for patients with good performance status of any age.

Treatment is similar to the approach for younger patients and includes maximal safe surgical resection, radiotherapy and temozolomide, although randomized studies failed to show a survival difference between biopsied and resected patients.

DOI: 10.1093/neuonc/noaf177

View source ↗